Source: https://stephendhebert.com/index.php/Uncategorised/composition-of-schedules-r-s-40-964.html
Timestamp: 2019-04-25 01:46:48+00:00

Document:
(32) Repealed by Acts 2011, No. 420, § 2, eff. July 15, 2011.
(8) Naphthylpyrovalerone whether or not further substituted in the naphthyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the naphthyl ring by one or more other univalent substituents or whether or not further substituted in the carbon chain at the 3, 4, or 5 position with an alkyl substituent.
(8) Benzoylindoles whether or not substituted in the indole ring to any extent or the phenyl ring to any extent.
(g) Repealed by Acts 1999, No. 755, § 2.
(5) Repealed by Acts 2001, No. 282, § 2.
(6) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy).
(1) Repealed by Acts 2006, No. 54, § 2.
(1) Immediate precursors to amphetamine and methamphetamine: phenylacetone.
For purposes of this Subsection, possession of immediate precursors sufficient for the manufacture of phenylacetone, piperidine, or cyclohexanone shall be deemed to be possession of such a derivative substance.
(4) Repealed by Acts 1982, No. 92, § 2.
(5) Repealed by Acts 2008, No. 67, § 2.
or any salt thereof and one or more active medicinal ingredients which are not listed in any schedule.
(3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt thereof, but not including butalbital when in combination with at least three hundred twenty-five milligrams of acetaminophen per dosage unit.
(6) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, which has been approved by the federal Food and Drug Administration.
(a) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid of opium.
(b) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(c) Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.
(d) Not more than 300 milligrams of hydrocodone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts such as acetaminophen or ibuprofen.
(e) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(h) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.
F. (1) Except as provided in Paragraph (2) of this Subsection, the term anabolic steroid does not include a substance listed in Subsection E above but which is expressly intended for administration to livestock or other nonhuman species and which has been approved by the secretary of health and hospitals for such an administration.
(2) If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of Subsection E above.
(3) A physician, dentist, or veterinarian shall not prescribe, dispense, deliver, or administer an anabolic steroid for human use or cause an anabolic steroid to be administered under his direction or supervision for human use except for a valid medical purpose and when required by demonstrable generally accepted medical indications. Bodybuilding, muscle enhancement, or increasing muscle bulk or strength through the use of an anabolic steroid by a person who is in good health is hereby declared not a valid medical purpose.
(1) Synthetic Dronabinol [delta-9-(trans) tetrahydrocannabinol] in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product.
(52) Repealed by Acts 2010, No. 810, § 2.
(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulphate per dosage unit.
E. (1) Ephedrine, pseudoephedrine, phenylpropanolamine. Unless listed in another schedule, any material, compound, mixture, or preparation containing any detectable quantity of ephedrine, pseudoephedrine, or phenylpropanolamine, their salts or optical isomers, or salts of optical isomers.
(2)(a) Nonprescription products containing ephedrine, pseudoephedrine, or phenylpropanolamine shall not be sold or distributed in a quantity greater than nine grams of ephedrine base, pseudoephedrine base, or phenylpropanolamine base to the same purchaser within any thirty-day period.
(b) Notwithstanding the prescription requirements for Schedule V controlled dangerous substances as provided for in R.S. 40:978(C), nonprescription products containing ephedrine, pseudoephedrine, or phenylpropanolamine may be dispensed without a prescription.
(3)(a) No person shall purchase, receive, or otherwise acquire more than nine grams of ephedrine base, pseudoephedrine base, or phenylpropanolamine base within any thirty-day period.
(b) This limit shall not apply to any quantity of such product, mixture, or preparation dispensed pursuant to a valid prescription written by a licensed health care professional having prescriptive authority.
(4) Wholesale drug distributors licensed by the Louisiana State Board of Wholesale Drug Distributors and registered with the United States Drug Enforcement Administration shall be exempt from the storage, reporting, record keeping, and physical security requirements for controlled dangerous substances for nonprescription products containing ephedrine, pseudoephedrine, and phenylpropanolamine which are not listed in another schedule.
(5) Except for sales log requirements and the transmittal of transaction information to the central computer monitoring system authorized by the provisions of Part X-F of Chapter 4 of Title 40 of the Louisiana Revised Statutes of 1950, pharmacies and pharmacists licensed by the Louisiana Board of Pharmacy and registered with the United States Drug Enforcement Administration shall be exempt from the storage, reporting, record keeping, and physical security requirements for controlled dangerous substances for nonprescription products containing ephedrine, pseudoephedrine, or phenylpropanolamine which are not listed in another schedule.
(6) The transaction information provided for in R.S. 40:1049.3 for the purchase of a nonprescription product containing ephedrine, pseudoephedrine, or phenylpropanolamine shall constitute an "order from a practitioner" as provided for in R.S. 40:970(C). Possession of a nonprescription product containing ephedrine, pseudoephedrine, or phenylpropanolamine pursuant to a valid transaction as provided for in R.S. 40:1049.3 shall be a defense for a violation of R.S. 40:970(C).
Acts 1972, No. 634, § 1. Amended by Acts 1973, No. 207, § 2; Acts 1977, No. 649, § 1; Acts 1978, No. 725, §§ 2, 3, eff. July 13, 1978; Acts 1979, No. 658, § 1; Acts 1979, No. 659, § 1; Acts 1980, No. 613, § 1; Acts 1980, No. 765, § 1; Acts 1981, No. 219, § 1; Acts 1981, No. 800, § 1, eff. Aug. 2, 1981; Acts 1982, No. 92, § 1; Acts 1982, No. 330, § 1; Acts 1984, No. 753, § 1; Acts 1985, No. 56, § 1, eff. June 18, 1985; Acts 1986, No. 732, § 1; Acts 1986, No. 1041, § 1; Acts 1987, No. 404, § 1; Acts 1988, No. 612, § 1; Acts 1990, No. 542, § 1; Acts 1991, No. 513, § 1; Acts 1991, No. 842, § 1, eff. July 23, 1991; Acts 1993, No. 156, § 1; Acts 1993, No. 288, § 1; Acts 1993, No. 616, § 1; Acts 1997, No. 398, § 1; Acts 1998, 1st Ex.Sess., No. 129, § 1; Acts 1999, No. 582, § 1; Acts 1999, No. 755, § 1; Acts 2000, 1st Ex.Sess., No. 13, § 1, eff. April 13, 2000; Acts 2001, No. 282, § 1; Acts 2001, No. 1036, § 1; Acts 2004, No. 702, § 1; Acts 2006, No. 54, § 1; Acts 2006, No. 56, § 1; Acts 2008, No. 67, § 1; Acts 2009, No. 153, § 1; Acts 2009, No. 165, § 1; Acts 2009, No. 314, § 1; Acts 2010, No. 565, § 1; Acts 2010, No. 810, § 1; Acts 2010, No. 866, § 1; Acts 2011, No. 420, § 1, eff. July 15, 2011; Acts 2012, No. 315, § 1; Acts 2012, No. 345, § 1, eff. May 28, 2012.

References: § 2
 § 2
 § 2
 § 2
 § 2
 § 2
 § 2
 § 1
 § 2
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1
 § 1